Finance

Challenges from investment firms to biopharma patents spur the industry to action to protect its drug franchises

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

The overall impression from the media is that the biotech industry is doing a great job inventing new drugs and treatments and that strong companies are getting the funding they need. But it's not that clear cut, writes Peter Young.

Fresh off Shire’s announcement to purchase NPS, CEO Dr. Flemming Ornskov sat down with PharmExec in San Francisco during the JP Morgan Healthcare Conference.

partnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity

Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.

After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed- small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up.

The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.

Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.

Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.

With revenues down and margins squeezed by a realigning payer pool, the power to price above the market is the ticket to the top-no discounts allowed.

In the next three months it is likely that three healthcare companies will face crucial activist votes. At Alere Inc., Coppersmith Capital Management, LLC wants the company to sell/divest assets which it believes could allow them to pay down over $3B in debt. In response, Alere is mounting a Hess style defense, nominating four new directors.

Pharm Exec's annual look at the trends and best practices in biopharm licensing and M&A for the year ahead.

Innovative pharmaceutical procurement has struggled to get the necessary mandate and attention from top management. But things may now be turning around, writes Philipp Polterauer.

Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.

Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead.

Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders.

With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead.

Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond

A panel of bankers and industry executives discuss what's ahead in deals for 2010.

Bill Trombetta expands his annual guide to stellar performance with the "Heavenly 27."

The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end.

Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.